Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...
Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the ...
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...
One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...
Daily Maverick on MSN33m
US funding cuts imperil African search for HIV vaccineA groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in ...
They're pushing for more funding to find effective treatments. Researchers are finally starting to make headway but have a ...
A small French biotech is trumpeting results from a trial suggesting its developmental drug could be used as part of an HIV cure. The phase 2a trial of AbiVax’s ABX464 pill is small but confirms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback